The anti-angiogenic peptide anginex greatly enhances Galectin-1 binding affinity for glycoproteins

Summary, in English

Angiogenesis is a key event in cancer progression and therefore a promising target in cancer treatment. Galectin-1, a β-galactoside binding lectin, is up-regulated in the endothelium of tumors of different origin and has been shown to be the target for anginex, a powerful anti-angiogenic peptide with anti-tumor activity. Here we show that when bound to anginex, galectin-1 binds various glycoproteins with hundred-to thousand-fold higher affinity. Anginex also interacts with galectin-2,-7,-8N, and-9N but not with galectin-3,-4, or-9C.

• Author: Emma Salomonsson; Victor L. Thijssen; Arjan W. Griffioen; Ulf J. Nilsson; Hakon Leffler
• Department/s: Division of Microbiology, Immunology and Glycobiology - MIG; Centre for Analysis and Synthesis; BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
• Publishing year: 2011
• Language: English
• Pages: 13801-13804
• Publication/Series: Journal of Biological Chemistry
• Volume: 286
• Issue: 16
• Links: http://www.ncbi.nlm.nih.gov/pubmed/21372130?dopt=Abstract; http://dx.doi.org/10.1074/jbc.C111.229096
• Document type: Journal article
• Publisher: American Society for Biochemistry and Molecular Biology
• Topic: Immunology in the medical area; Microbiology in the medical area
• Status: Published
• ISBN/ISSN/Other: ISSN: 1083-351X